NEWS and PRESS RELEASES

CEBINA covid square.png

04 July 2022

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by  major variants of SARS-CoV-2
Read more

CEBINA covid square.png

03 February 2022

Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of
SARS-CoV-2

Read more

DL square for CEBINA website.png

14 June 2021

CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
Read more

DL square for CEBINA website.png

19 April 2022

Danube Labs: Call for Proposals
Read more

 

CEBINA covid square.png

10 December 2021

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
Read more

CEBINA covid square.png

4 May 2021

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing
Read more

EVQ%20green%20square_edited.jpg

23 February 2022

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC
Read more

CEBINA covid square.png

17 August 2021

Widely available anti-allergy azelastine nasal spray poised to revolutionize COVID-19 management
Read more

 

CEBINA covid square.png

17 February 2021

URSAPHARM Arzneimittel
and CEBINA announce partnership to repurpose the antihistamine azelastine to combat COVID-19

Read more